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Developing a topic-based repository of
clinical trial individual patient data:
experiences and lessons learned from a
pilot project
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Abstract
Background: Building a dataset of individual participant data (IPD) for meta-analysis represents considerable
research investment as well as collaboration across multiple institutions and researchers. Making arrangements to
curate and share the dataset beyond the IPD meta-analysis project for which it was established, for reuse in future
research projects, would maximise the value of this investment.
Methods: Our aim was to establish the Cochrane repository for individual patient data from clinical trials in
pregnancy and childbirth (CRIB) as an example of how an IPD repository could become part of Cochrane
infrastructure. We believed that establishing CRIB under Cochrane auspices would engender trust and encourage
trial investigators to share data, and at the same time position Cochrane to take steps towards expanding the
number of reviews with IPD synthesis.
Results: CRIB was designed as a web-based platform to receive, host and facilitate onward sharing of de-identified data.
Development was not straightforward and we did not fully achieve our aim as intended. We describe the challenges
encountered and suggest ways that future repositories might overcome these. In particular, securing the legal agreements
required to facilitate data sharing proved to be the main barrier, being time-consuming and more complex than anticipated.
Conclusions:We would recommend that researchers conducting IPD meta-analysis should consider discussing the option
to transfer the curated IPD datasets to a repository at the end of the initial meta-analysis and this should be recognised
within the data sharing agreements made with the original data contributors.
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Background
Individual patient data (IPD) meta-analyses are used in-
creasingly in systematic reviews. Obtaining IPD from tri-
als allows collection of unreported information, more
detailed evaluation of trial integrity, and standardisation
across trials, including covariate and outcome defini-
tions. IPD permits more detailed and flexible analysis
including time-to-event analysis and modelling
individual-level variation in outcomes. A great deal of
time, effort and resource is invested in assembling,
checking and standardising the IPD across trials and the
resultant IPD dataset is a valuable resource, with poten-
tial use beyond the project for which it was established.
This is particularly apparent when the process of assem-
bling the IPD dataset has added new information such
as additional follow-up data that have not been previ-
ously analysed. This harmonised IPD dataset can be
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effectively considered as a new ‘study’ and considerable re-
search effort is wasted when such data are not made avail-
able beyond the end of the IPD meta-analysis project.
In recent years, a number of data repositories and data-
sharing platforms have been established to store, curate
and share data from completed clinical trials. These focus
on storing or providing access to IPD in its original format
as recorded by each individual trial, and they are geared
towards sharing data from individual trials rather than
harmonised datasets from groups of trials addressing the
same research question. The establishment of these re-
sources is a welcome development. However, the format
and coding of IPD is likely to differ between stored trials
and will need to be re-coded for use in any new IPD
meta-analysis or other research projects that wish to use a
dataset, comprising multiple trials, addressing similar
questions in its entirety. The new research team may still
need to consult with the original trial investigators, to
clarify issues, recode variables and obtain any required in-
formation that is missing from the repository materials.
Restrictions on how repository data may be used, particu-
larly having to analyse data within a secure repository
space, may potentially limit their usefulness for some types
of IPD meta-analysis projects. Having to repeat data
checking and harmonisation processes for each new pro-
ject is wasteful of prior research effort if trials have previ-
ously been included in an IPD meta-analysis—for both the
new research team and the original trial investigators. Fur-
thermore, existing repositories have thus far been much
more successful in securing data from commercial trials
than from academic trials.
There is therefore space to establish repositories that
provide long-term storage and curation of the data col-
lected during IPD meta-analyses, or other similar pro-
jects that bring together data across multiple studies,
with an option to add relevant new trials as they are
completed. A number of such topic-based repositories
exist, but they mostly focus on reusing the data for on-
going research collaboration within the group that estab-
lished the original IPD meta-analysis. This reuse builds
on the trust established during the original IPD meta-
analysis, whereby the original trial investigators who are
the data owners are comfortable with the central team
who manage the data repository making decision about
reuse on their behalf (although they may also have a
right of veto on inclusion in new projects).
We know from experience that trial investigators are
often wary of sharing data and need reassurance about
exactly how their data will be used and what for. This
often forms the basis of the data sharing agreements
(DSA) that are put in place between IPD meta-analysis
teams and trial investigators. These DSAs generally
stipulate that the IPD will be used only for the project in
hand, used in accordance with its protocol and not
shared beyond the project. They also often set out the
nature of collaborating and the academic credit that will
accrue from participation, such as authorship
arrangements.
Establishing repositories of trial data seeded by IPD
meta-analysis projects that aim to share data beyond the
collaborative group would be in the public interest, and
has already been shown to be supported by the research
community [1]. We believed that doing so under the
auspices of Cochrane, a worldwide trusted organisation
that specialises in systematic review, could enhance the
chances of success. We thought that academic clinical
trial investigators might be more willing to share their
data and to delegate authority to approve third party re-
quests to access and use it, to Cochrane as opposed to
other organisations. This trust could be built on
Cochrane’s general reputation and on the fact that gov-
ernance processes could build on the considerable topic
and methodological expertise that resides within the
Cochrane community. At the same time, building such
repositories could facilitate expansion of IPD meta-
analysis within Cochrane reviews, and over time support
exciting possibilities for IPD network meta-analyses and
living IPD reviews.
Methods
The objective was to establish an online platform
(CRIB—Cochrane repository for individual patient data
from clinical trials in pregnancy and childbirth) to facili-
tate the sharing of IPD datasets under the auspices of
the Cochrane collaboration, using the EPPPIC (Evaluat-
ing Progestogens for Prevention of Preterm birth Inter-
national Collaborative) [2] IPD dataset as an exemplar,
with a view to further expansion in the future. EPPPIC
was set up to evaluate whether, and under what condi-
tions, different forms of progestogen may be effective in
preventing preterm births and associated neonatal com-
plications. The EPPPIC project was conducted by a re-
search team based at the University of York, endorsed
and advised by an international Secretariat and funded
by the Patient-Centered Outcomes Research Institute
(PCORI).
To inform the development of CRIB, we examined the
functionality of three major data sharing platforms (Vivli
[3], UK Data Service [4], and Clinical Study Data Re-
quest (CSDR) [5]) as summarised in Table 1. Building
on this, along with our personal experiences, recognition
of FAIR Data principles [6], input from our advisory
committee, and our previous work to elicit standards
and preferences of the data sharing community [1, 7],
we chose a ‘safeguarded’ data sharing model, where data
users navigate an approvals process before being granted
access to data. Our proposed data access process, includ-
ing a Cochrane-affiliated peer review process and
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governance procedures are outlined in Fig. 1, and a brief
comparison of CRIB features against other repositories
is provided in Table 1. Development of CRIB, and the
challenges therein, focussed on the following main areas:
Results
Platform
An online platform is required to manage requests, the
approval process and data transfer between owners and
users. A web-based application was developed so that
changes in both governance and functionality could be
easily accommodated. Given the nature of project, this
approach proved to be useful as the requirements and
functionality did indeed change during the lifespan of
the exercise.
The approval process was developed to require a two-
stage verification of the user’s request for data. Firstly,
by simple verification of their email address and latterly
an ‘offline check’ of the request by the CRIB team to es-
tablish the veracity and creditability of the requesting
party.
The application itself has been developed using standard
web technologies (principally Microsoft and Oracle) and
hosted within the UoL data centre, in order to support the
required level of security for a system such as this.
Governance
Having had initial supportive conversations with mem-
bers of the Cochrane Editorial and Methods Unit, our
intention was that Cochrane would have an overarching
responsibility for governance, and that the Pregnancy
and Childbirth Group could be supported to manage the
repository on a day to day basis. When explored in
greater detail, the Cochrane legal department advised
that they would not be willing to take the role of CRIB
legal entity. This was a critical set-back as a main prem-
ise for the work was that entering into agreement with
Cochrane would be a major incentive for trial investiga-
tors to share their data.
Cochrane proposed to fund the CRIB data being de-
posited through a recently established data sharing plat-
form—Vivli [3]. Vivli presented Cochrane and CRIB
with working drafts of both depositor and user agree-
ments. We learned that Vivli’s $35,000 fee would not
cover the costs of administrative support to manage se-
cured data sharing. Another important point was that
Vivli’s model included a fee for each individual trial in
the dataset, even though the IPD derived dataset com-
prised all trials and could be treated as a single data set.
The purpose of this pilot was to enable sharing of an
IPD dataset comprising multiple trials.
In parallel, we explored the support offered by the UK
Data Service [4], which included the opportunity to es-
tablish a dedicated ‘Cochrane collection’ that would host
the EPPPIC IPD dataset under safeguarded management,
along with an assessment of the risks of disclosure of the
IPD dataset, Cochrane branding on the UKDS [4] web-
site, and limited administrative support for vetting and
Table 1 Data sharing platform comparison table
CRIB Vivli UK data service CSDR






Functionality for controlled analyses
within a secure platform
No Yes Yes For pharmaceutical trials: Yes
For non-commercial trials: No2




offered for a fee
Yes Yes
(advice on de-identification)
Trusted repository status (i.e.
international standard ISO 16363)
No Unclear Yes CSDR is not a repository; they
signpost users to data owners
International standard for meta-data
(e.g. DDI)
Not achieved Yes Yes Unclear
International standard digital object
identifier (DOI)
Not achieved Yes Yes Yes
Who is the legal entity University of
Liverpool
Vivli University of Essex Agreement between data owner and
data user
Who manages approvals Cochrane pregnancy
and childbirth
Data owner or Wellcome UKDS Data owner or Wellcome
Researcher training No No Yes No
1Open data, can be downloaded freely by anyone; Safeguarded data, downloadable but require an approvals process and legal agreements to structure data use
(such as a licence agreement); Controlled data, pose disclosure risk to the organisation and can only be accessed by approved data users within a secured
research environment (no download option and data use takes place in a secured setting)
2MRC, Cancer Research UK, Bill and Melinda Gates are piloting deposit of trial data with CSDR. Wellcome provide support and managed the independent
review panel
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sharing proposals to access data. The UKDS could assign
the digital object identifier (DOI), create meta-data and
had established legal agreements for data depositors that
could be adopted and used.
Legal
Whilst trying to create a feasible, user-friendly legal
framework, we identified a few key obstacles. First, be-
cause the original EPPPIC data transfer agreements were
developed and in use before CRIB was established, we
had to seek additional permissions from the trial investi-
gators to pass the data on to CRIB. Second, CRIB’s com-
mitment to a model of safeguarded data sharing rather
than open data sharing created requirements for add-
itional legal agreements. The negotiations between legal
teams from the University of York (EPPPIC), the Univer-
sity of Liverpool (CRIB) and Cochrane began early in the
project, yet securing a workable legal framework for this
model of data sharing was only been partially achieved
after almost 3 years. An overview of the legal agreements
required for the CRIB system is summarised in Table 2.
Recognition
Issues around assigning a DOI to the EPPPIC dataset, to
enhance discoverability, were also problematic without
backing from Cochrane as a legal entity, as the responsi-
bility of assigning a DOI rests with an institution or or-
ganisation. As University of York (UoY) would not be
the data host, it was not possible to issue a DOI. On the
other hand, as UoY had a stake in the intellectual prop-
erty through the value added by data harmonisation,
University of Liverpool was not prepared to issue a DOI
either. Consequently, no institution involved in our pilot
project would agree to assign the EPPPIC/CRIB dataset
a DOI, thus limiting the findability of the dataset, one of
the key FAIR principles [6].
Conclusions
Our experience confirms that many trial investigators
support data sharing and reuse.
Our project intended to develop and pilot a mechan-
ism for sharing a derived IPD dataset comprising mul-
tiple trials to facilitate reuse and maximise value from
the research effort invested in conducting the individual
trials and in establishing the harmonised IPD dataset.
Our aim was not to compete with established platforms
for sharing individual trials’ data, but to provide a frame-
work for facilitating reuse of existing IPD datasets in fu-
ture data synthesis, primarily by linking them to the
relevant Cochrane review groups.
Despite the setbacks we encountered, we argue that
Cochrane remains well positioned to lead the way in fa-
cilitating sharing trial data for use in IPD meta-analyses
within systematic reviews. This would be contingent on
reaching a shared view on sustainable hosting and main-
tenance of datasets. This would build on and enhance
Fig. 1 CRIB access process
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Cochrane’s reputation as an honest broker and global
champion of ‘trusted evidence.’ A starting point for this
would be to facilitate discussion within the Cochrane
community about the value of such an endeavour. Hope-
fully, this process would increase pressure to find solu-
tions to perceived legal stumbling blocks. At the same
time, a detailed investigation of the various legal and data
sharing agreements that need to be put in place, outside
of the constraints of a time limited pilot project would be
helpful, potentially including the development of a suite of
generic legal agreements based on the templates from this
pilot. Exploration of how DOIs for IPD meta-analysis
datasets can be generated would also be valuable.
Finally, whilst we have demonstrated that the principles
and technological side of establishing an online data shar-
ing platform is feasible and relatively straightforward, we
know that there are existing offerings available that could
be adapted to suit the purpose intended. Subcontracting
this aspect of the process carries a risk of diluting the
value of Cochrane involvement as trial investigators would
be entering into an agreement with external repositories.
Nevertheless, with careful branding and transparency of
involvement from Cochrane, this model could still be
worthwhile. Our work has highlighted that some of these
currently available offerings are costly and the important
discussion of who should cover the financial commitment
of sharing datasets of curated multiple trials, has only just
started. We have identified the UK Data Service as a po-
tentially suitable facility with several positive features that
would be very worthy of further exploration.
Following further positive discussion with Cochrane, the
current legal and contractual barriers to efficient use of IPD
in systematic reviews have been acknowledged and Cochrane
have confirmed they are committed to contributing to solu-
tions. We believe that taking forward the discussions regard-
ing hosting well-governed IPD repositories with Cochrane,
or with another suitably trusted organisation, would reduce
research waste, increase opportunities for IPD syntheses, and
provide better evidence to inform decision-making.
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Table 2 The legal agreements required to facilitate proposed safeguarded data sharing through CRIB
Stakeholder Document to sign
Trial data owners • Data sharing agreement to create the IPD dataset
• Data release form to permit transfer of cleaned, derived dataset to the repository
• Depositor agreement with the Institution hosting the repository
Institution hosting the IPD data set (e.g. University) Data transfer agreement
Institution hosting the repository (e.g. Cochrane) Data transfer agreement
Approved data users Research data access agreement with the Institution hosting the repository
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